Observational study on severe community-acquired pneumonia
Fulminant Cases Among Severe Community-acquired Pneumonia - an Observational Retrospective Study
University of Trieste · NCT06516601
This study is gathering information on patients with severe pneumonia to see how it affects their health and treatment, including those with COVID-19 and other types of pneumonia.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1460 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Trieste (other) |
| Locations | 2 sites (Trieste, TS and 1 other locations) |
| Trial ID | NCT06516601 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather data on patients with severe community-acquired pneumonia (CAP) across five centers from January 2018 to July 2024. It focuses on cases of fulminant pneumonia, which can rapidly progress to acute respiratory distress syndrome (ARDS) and septic shock. The study collects clinical data such as oxygenation state, vital signs, and comorbidities to better understand the incidence and treatment of this severe condition. Patients with both COVID-19 and non-COVID pneumonia are included if they meet specific clinical criteria.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with severe community-acquired pneumonia who exhibit rapid deterioration.
Not a fit: Patients with hospital-acquired or healthcare-acquired pneumonia, as well as those with chronic end-stage illnesses, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve understanding and treatment strategies for severe community-acquired pneumonia, potentially reducing hospital mortality rates.
How similar studies have performed: While there is limited data on fulminant pneumonia specifically, other studies on severe pneumonia and ARDS have shown promising results in understanding and managing these conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: severe community acquired pneumonia according to ATS/IDSA - Exclusion Criteria: incomplete outcome data \-
Where this trial is running
Trieste, TS and 1 other locations
- Marco Confalonieri — Trieste, TS, Italy (RECRUITING)
- SC Pneumologia, Azienda Sanitaria Universitaria Giuliano-Isontina — Trieste, Italy (RECRUITING)
Study contacts
- Principal investigator: MARCO CONFALONIERI, MD — University of Trieste
- Study coordinator: MARCO CONFALONIERI, MD
- Email: mconfalonieri@units.it
- Phone: +390403994667
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Community-acquired Pneumonia, Severe Pneumonia, ARDS, Human, Sepsis, fulminant pneumonia, community acquired pneumonia, ARDS, sepsis